Catalyst Pharmaceuticals (CPRX) Competitors $21.05 -0.10 (-0.47%) (As of 10:02 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CPRX vs. IDYA, ANIP, PGNX, CUE, DRRX, RVMD, QGEN, ITCI, ROIV, and ASNDShould you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include IDEAYA Biosciences (IDYA), ANI Pharmaceuticals (ANIP), Progenics Pharmaceuticals (PGNX), Cue Biopharma (CUE), DURECT (DRRX), Revolution Medicines (RVMD), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector. Catalyst Pharmaceuticals vs. IDEAYA Biosciences ANI Pharmaceuticals Progenics Pharmaceuticals Cue Biopharma DURECT Revolution Medicines Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Catalyst Pharmaceuticals (NASDAQ:CPRX) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Is CPRX or IDYA more profitable? Catalyst Pharmaceuticals has a net margin of 31.01% compared to IDEAYA Biosciences' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.79% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Catalyst Pharmaceuticals31.01% 40.79% 34.87% IDEAYA Biosciences N/A -19.42%-18.63% Do insiders & institutionals have more ownership in CPRX or IDYA? 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, CPRX or IDYA? Catalyst Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Which has preferable earnings & valuation, CPRX or IDYA? Catalyst Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalyst Pharmaceuticals$398.20M6.33$71.41M$1.1817.92IDEAYA Biosciences$23.39M94.37-$112.96M-$2.33-10.96 Does the media refer more to CPRX or IDYA? In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 9 mentions for Catalyst Pharmaceuticals and 8 mentions for IDEAYA Biosciences. Catalyst Pharmaceuticals' average media sentiment score of 0.59 beat IDEAYA Biosciences' score of 0.10 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor CPRX or IDYA? Catalyst Pharmaceuticals received 356 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 74.70% of users gave Catalyst Pharmaceuticals an outperform vote while only 70.98% of users gave IDEAYA Biosciences an outperform vote. CompanyUnderperformOutperformCatalyst PharmaceuticalsOutperform Votes49374.70% Underperform Votes16725.30% IDEAYA BiosciencesOutperform Votes13770.98% Underperform Votes5629.02% Do analysts recommend CPRX or IDYA? Catalyst Pharmaceuticals currently has a consensus price target of $31.14, suggesting a potential upside of 47.25%. IDEAYA Biosciences has a consensus price target of $53.67, suggesting a potential upside of 110.13%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94 SummaryCatalyst Pharmaceuticals beats IDEAYA Biosciences on 13 of the 19 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPRX vs. The Competition Export to ExcelMetricCatalyst PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.52B$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio17.9210.78135.4117.82Price / Sales6.33243.751,160.9774.56Price / Cash10.0222.1633.5332.53Price / Book6.415.474.674.68Net Income$71.41M$153.61M$119.07M$226.08M7 Day Performance-2.49%-2.00%-1.83%-1.04%1 Month Performance0.62%-7.46%-3.60%1.04%1 Year Performance53.93%31.82%31.66%26.28% Catalyst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPRXCatalyst Pharmaceuticals4.7417 of 5 stars$21.05-0.5%$31.14+47.9%+54.3%$2.51B$398.20M17.84167Analyst ForecastIDYAIDEAYA Biosciences4.1494 of 5 stars$25.59+0.2%$53.67+109.7%-17.1%$2.21B$23.39M0.0080Analyst ForecastANIPANI Pharmaceuticals4.3361 of 5 stars$55.24+0.3%$77.33+40.0%+7.4%$1.16B$486.82M0.00642Positive NewsPGNXProgenics PharmaceuticalsN/A$4.10flatN/A+0.0%$355.05M$34.99M-5.1379Gap UpHigh Trading VolumeCUECue Biopharma4.4371 of 5 stars$1.05-3.3%$5.00+374.3%-55.3%$51.28M$5.49M-1.2160Gap UpDRRXDURECT3.0843 of 5 stars$0.86-4.7%$5.00+480.7%+39.5%$26.73M$8.55M0.0080Analyst ForecastAnalyst RevisionNews CoverageRVMDRevolution Medicines2.7869 of 5 stars$57.77+1.2%$61.00+5.6%+162.6%$9.72B$11.58M0.00443QGENQiagen4.4347 of 5 stars$42.22+0.3%$50.88+20.5%+2.5%$9.63B$1.97B107.975,967Positive NewsITCIIntra-Cellular Therapies4.4737 of 5 stars$85.37-0.3%$97.23+13.9%+46.2%$9.05B$464.37M-98.44560Positive NewsROIVRoivant Sciences3.2845 of 5 stars$11.67+1.6%$17.93+53.6%+30.6%$8.63B$124.79M2.03860ASNDAscendis Pharma A/S3.0066 of 5 stars$123.47-0.7%$191.77+55.3%+32.7%$7.49B$288.08M0.00640Analyst Upgrade Related Companies and Tools Related Companies IDYA Alternatives ANIP Alternatives PGNX Alternatives CUE Alternatives DRRX Alternatives RVMD Alternatives QGEN Alternatives ITCI Alternatives ROIV Alternatives ASND Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CPRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
